Authors conducted a multicenter retrospective analysis of patients with cT1 renal cell carcinoma (RCC) undergoing partial or radical nephrectomy. All patients were stratified by tumor size into three groups cT1a (≤2cm, very low risk), cT1b (2cm< and ≤5cm, low risk), and cT1c (5cm< and ≤7cm, intermediate risk). The primary outcome was recurrence-free survival (RFS) and the secondary outcome was overall survival (OS).
A total of 4710 patients were stratified into proposed T1 groups (T1a=856, T1b=2909, T1c=945; median follow-up 39 months). There was a significant difference in 5-years RFS depending on the stage (95.7%, 90.8%, and 80.8% in cT1a, cT1b and cT1c tumors, respectively [p<0.001], Figure 1a). The similar differences in 5-years OS were found (89.3%, 85.5%, and 73.3%, respectively [p=<0.001], Figure 1b).


Multivariable Cox Regression analysis showed that increasing tumor stage (Referent T1a; cT1b HR=1.927 p=0.002, cT1c HR=3.687 p<0.001) was independent risk factor for RFS as well as increasing age (HR=1.02, p<0.001), diabetes mellitus (HR=1.41, p=0.017), high tumor grade (HR=2.65, p<0.001).
According to Kaplan-Meier analysis, increasing age (HR=1.05), diabetes mellitus (HR=1.57), high tumor grade (HR=1.80 (p<0.001 for all) and increasing tumor stage (Referent T1a; cT1b HR=1.10 p=0.44, cT1c HR=1.747 p<0.001) were independent risk factors for OS.
Subdivision of cT1 RCC into three clinical stage categories allows respecting the different biological potential which varies significantly. A proposed classification may influence treatment tactics and change postoperative follow-up protocols by delineating a very low risk and intermediate risk subset of renal tumors. Although a prospective observational study is needed, it is hard to carry it out because a large proportion of patients with very low-risk tumors (< 2 cm) with small tumors currently choose active surveillance, as suggested in EAU Guidelines.
Presented by: Ithaar H. Derweesh, MD, Urologic Oncologist, Professor of Urology and Radiology, the University of California San Diego, Department of Urology, San Diego, United States
Written by: Kirill Shiranov, MD, Fellow, Department of Urology, Rostov University, Rostov on Don, Russia, at the 34th European Association of Urology (EAU 2019) #EAU19 conference in Barcelona, Spain, March 15-19, 2019.